An interventional study of Mindfulness Based-Cognitive Therapy (MBCT) and Emotion Focused Therapy Group for Cancer Recovery (EFT-CR) in Cancer, sponsored by Instituto Portugues de Oncologia, Francisco Gentil, Porto. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-10-22.
Sponsored by Instituto Portugues de Oncologia, Francisco Gentil, Porto · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Background: There is some evidence demonstrating the effect of psychological interventions in improvements in health biological parameters. To best of our knowledge, no study had addressed the impact of any psychological intervention on extracellular vesicles. In addition, Mindfulness-Based Cognitive Therapy (MBCT) and Emotion Focused Therapy for Cancer Recovery (EFT-CR) in the group have never been explored regarding extracellular vesicles and the effectiveness of these was not compared yet.
Objectives:
Methods: The design of this study is a parallel randomized controlled trial. Participants will be randomized into MBCT, EFT-CR or usual care. Outcome measures will be assessed before, at the end of the intervention (8 weeks) and follow-ups (24 and 52 weeks from the baseline moment).
Hypotheses: The researchers expected that both interventions will have an effect on extracellular vesicles and other study biomarkers as well as improvements in psychological outcomes, compared to treatment as usual (TAU) group. Regarding the comparative effectiveness, we did not have evidence to hypothesize which one of the interventions will be superior in both biological (extracellular vesicles) and psychological outcomes.
Contribution for practice: The results of this preliminary study would permit to know if there are benefits of these psychological interventions on changes in extracellular vesicles and on psychological outcomes related to health. In addition, this study will permit to determine the acceptability of conducting a larger randomized controlled trial.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
This study's planned enrollment of 108 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Instituto Portugues de Oncologia, Francisco Gentil, Porto is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Compared within Prostatic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Study Population Description: Participants will be recruited in the Portuguese Oncology Institute of Porto (Porto, Portugal), which is a reference public hospital in the north of the country offering cancer treatments.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group therapy based on Mindfulness Based-Cognitive Therapy (MBCT).
Behavioral: Mindfulness Based-Cognitive Therapy (MBCT)
Group therapy based on Emotion Focused Therapy for Cancer Recovery (EFT-CR).
Behavioral: Emotion Focused Therapy Group for Cancer Recovery (EFT-CR)
Treatment as Usual is the condition in which participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral and intervention for people identified with significant distress difficulties.
Other: Treatment as usual (no intervention)
MBCT is a program developed by Zindel Segal, Mark Williams and John Teasdale. During MBCT patients learn to decenter their negative thoughts and feelings, allowing the mind to move from an automatic thought pattern to conscious emotional processing. Mindfulness practices included in this program are breath awareness, body scan, sitting and walking meditation, and mindful yoga. The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.
EFT-CR is an evidence-based approach to psychotherapy, which combines aspects of person-centered, gestalt and existential therapies with contemporary emotion theory and dialectical constructivism (Elliott et al, 2004, Rice \& Greenberg, 1984). On EFT-CR, therapist follows the client experience and guides the process, proposing therapeutic tasks when specific client behaviors occur. EFT-CR uses a set of emotion change principles which guide a process of emotional deepening process, from undifferentiated distress to secondary reactive emotions to primary maladaptive emotions to core pain and thence to primary adaptive emotions and emotional transformation (Elliott \& Greenberg 2016). The intervention will have the following structure: 8 weekly face-to-face meetings of 2 hours in a group format, daily home-based practice of learned skills, 4 hours of retreat/intensive group work after the fifth week, 6 months of home practice, 4 monthly consolidation face-to-face sessions.
Treatment as Usual is the condition in which participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral and intervention for people identified with significant distress difficulties.
Change on Extracellular vesicles number by ultracentrifugation with sucrose cushion
The collected extracellular vesicles will be quantified by Nanoparticle tracking analysis (Nanosight Ltd.), and data will be measured in particles per milliliter (mL). NTA measures Brownian movements on a particle-by-particle basis tracking movements by image analysis. Additionally, miR21-5p - a brain related microRNA - will be measured to ascertain for the extracellular vesicle's origin. The latter will be achieved by isothermal DNA amplification method, and data will be measured by luminescence (in RLU - relative light unit).
Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0
Change on anxiety, depression and stress (Depression Anxiety Stress Scales, DASS21)
This self-report instrument assess the depressive, anxiety and stress symptoms in a 4-points likert scale, from 0 to 3, with higher values representing higher depression, anxiety and stress symptoms
Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0
Change on Cancer antigen (CA 15-3)
This indicator assess CA 15-3 (units/mL) using an immunoassay analyzer
Time frame: T0-before intervention;T2-24 weeks after T0; T3-52 weeks after T0
Change on Prostate-specific antigen (PSA)
This indicator assess PSA (ng/mL) using an immunoassay analyzer
Time frame: T0-before intervention;T2-24 weeks after T0; T3-52 weeks after T0
Change on Carcinoembryonic Antigen assays (CEA)
This indicator assess CEA (ng/mL) using an immunoassay analyzer
Time frame: T0-before intervention;T2-24 weeks after T0; T3-52 weeks after T0
Change on Adrenocorticotropic Hormone (ACTH)
This indicator assess ACTH (pg/mL) using an immunoassay analyzer
Time frame: T0-before intervention;T2-24 weeks after T0; T3-52 weeks after T0
Transcript inflammatory response genes (IL-1, IL-6, IL-8, IL-10, IFNγ and TNF)
These indicators assess inflammatory response genes in plasma by Quantitative RT-PCR assays of the same individuals using TaqMan™ Gene Expression Assays
Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0
Change on Analytic biomarkers (Erythrocytes number)
This indicator assess erythrocytes number (million/mm3) from blood samples(Sysmex XN)
Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0
Change on Analytic biomarkers (PCR number)
This indicator assess PCR (mg/L) from blood samples
Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0
Change on Analytic biomarkers (telomerase activity)
This indicator assess telomerase activity (units) from blood samples
Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0
Change on Analytic biomarkers (hemoglobin glycosylated (HPLC))
This indicator assess HPLC (mmol/mol) from blood samples
Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0
Change on Global distress (Clinical Outcome Routine Evaluation - Outcome Measure, CORE-OM)
This self-report measure assesses global distress in four domains: subjective well-being, symptoms, social/life functioning, risk to self and others, rated in 5-points likert scale from never to always. Higher scores meaning higher psychological suffering
Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0
Change on quality of life (Functional Assessment of Cancer Therapy, FACT)
These self-report instrument assess perceived quality of life related to the cancer, in a 5-points likert scale, from 0 to 4, with higher value indicated higher quality of life
Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0
Change on quality of life (Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being Scale, FACIT-SP)
These self-report instruments assess perceived spiritually related to the cancer in a 5-points likert scale, from 0 to 4, with higher value indicated higher well-being
Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0
Change on fear of cancer recurrence (Fear of Cancer Recurrence, FCR-7)
This self-report instrument assess the fear of cancer recurrence, rated in a 5-points likert scale, with higher values indicated higher fear of recurrence
Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0
Change on satisfaction perceived social support (ESSS)
This self-report instrument assess the perceived level of social support, rated in a 5-points likert scale, with higher values meaning higher social support
Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0
Change on emotional regulation processes (Emotion Regulation Questionnaire, ERQ, emotion suppression subscale)
This self-report measure assess the emotion regulation processes rated in a 7-points likert scale, with higher values representing higher emotional suppression
Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0
Change on impact of events (Impact of Event Scale - Revised, IES-R)
This self-report measure assess the impact of significant events, rated in a 5-points likert scale, with higher scores meaning higher negative impact of the event
Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0
Change on Mindfulness Attention and Awareness (Mindfulness Attention and Awareness Scale, MAAS)
This self-report measure assess the mindfulness and awareness skills, rated in a 6-points likert scale with higher scores indicating higher attention and awareness
Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0
Change on self-compassion skills (Self-Compassion Scale - Short Form, SHORT FORM)
This self-report measure assess the self-compassion skills, rated in 5-points likert scale, with higher scores indicating higher self-compassion
Time frame: T0-before intervention; T1-8 weeks after T0; T2-24 weeks after T0; T3-52 weeks after T0
Change Interview (Elliot, 1999)
This interview assesses the psycho-therapeutic changes perceived by participants after psychological intervention. The interview questions explore the changes that a person has noticed since therapy began, what the person attributes these changes to, and helpful and unhelpful aspects of therapy, in a qualitative way. In addition, the participants identified therapeutic changes as result of the therapy and are asked to rate these changes in three scales: expected change (1: change totally expected; 5: totally unexpected); change without therapy (1: the change would not have happened; 5: change would happen for sure); and the value of the change (1: nothing important; 5: extremely important).
Time frame: T2-24 weeks after T0
Change on smoking dependency (Fagestrom Test)
This instrument assesses nicotine dependency with 6 items (rated from 0 to 2 or 3). The total score range is 1-10, with higher values meaning higher nicotine dependency
Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0
Change on physical activity (IPAQ,The International Physical Activity Questionnaire)
This instrument assesses physical activity in 7 items, with higher scores meaning higher level of physical activity
Time frame: T0-before intervention; T2-24 weeks after T0; T3-52 weeks after T0
No study locations are listed for this record.
Start is estimated for Sep 2021; primary completion for Sep 2021, 0 months later.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 0 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto Portugues de Oncologia, Francisco Gentil, Porto